Stockholm - Delayed Quote SEK

Camurus AB (publ) (CAMX.ST)

609.50
-15.00
(-2.40%)
At close: June 13 at 5:29:52 PM GMT+2
Currency in SEK All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
2,035,938
1,867,581
1,716,850
956,340
600,570
Cost of Revenue
137,931
129,507
122,348
103,265
85,352
Gross Profit
1,898,007
1,738,074
1,594,502
853,075
515,218
Operating Expense
1,274,158
1,274,444
1,061,092
781,811
627,575
Operating Income
623,849
463,630
533,410
71,264
-112,357
Net Non Operating Interest Income Expense
80,238
83,357
23,401
1,169
-1,194
Pretax Income
709,622
552,522
549,304
73,125
-111,768
Tax Provision
161,839
124,128
117,862
17,572
-21,322
Net Income Common Stockholders
547,783
428,394
431,442
55,553
-90,446
Diluted NI Available to Com Stockholders
547,783
428,394
431,442
55,553
-90,446
Basic EPS
9.38
--
7.78
1.01
-1.66
Diluted EPS
9.17
--
7.50
0.97
-1.66
Basic Average Shares
58,415.33
--
55,476.54
55,067.40
54,450.73
Diluted Average Shares
59,706.20
--
57,497.49
57,170.62
56,227.74
Total Operating Income as Reported
629,384
469,165
525,903
71,956
-110,574
Total Expenses
1,412,089
1,403,951
1,183,440
885,076
712,927
Net Income from Continuing & Discontinued Operation
547,783
428,394
431,442
55,553
-90,446
Normalized Income
547,783
428,394
431,442
50,262.64
-90,446
Interest Income
82,296
84,368
24,715
2,657
171
Interest Expense
2,046
999
1,275
1,212
1,365
Net Interest Income
80,238
83,357
23,401
1,169
-1,194
EBIT
711,668
553,521
550,579
74,337
-110,403
EBITDA
728,265
568,158
564,566
87,273
-97,722
Reconciled Cost of Revenue
137,931
129,507
122,348
103,265
85,352
Reconciled Depreciation
16,597
14,637
13,987
12,936
12,681
Net Income from Continuing Operation Net Minority Interest
547,783
428,394
431,442
55,553
-90,446
Total Unusual Items Excluding Goodwill
--
--
0
6,961
--
Total Unusual Items
--
--
0
6,961
--
Normalized EBITDA
728,265
568,158
564,566
80,312
-97,722
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
1,670.64
0
12/31/2021 - 12/3/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

XBRANE.ST Xbrane Biopharma AB (publ)
0.2420
-3.20%
 
TBPH Theravance Biopharma, Inc.
10.69
+0.75%
 
HNSA.ST Hansa Biopharma AB (publ)
24.46
-1.37%
 
ACTI.ST Active Biotech AB (publ)
0.2385
-4.22%
 
VICO.ST Vicore Pharma Holding AB (publ)
8.52
-3.62%
 
ACE.ST Ascelia Pharma AB (publ)
4.4150
-3.71%
 
BINV.ST BioInvent International AB (publ)
36.45
-4.20%
 
EGTX.ST Egetis Therapeutics AB (publ)
4.5350
-7.07%
 
CANTA.ST Cantargia AB (publ)
1.0660
-2.20%
 
CNTA Centessa Pharmaceuticals plc
12.38
+2.82%